查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018532

前列腺癌診斷市場：全球市場預測（按產品類型、檢測類型、技術、最終用戶和應用分類），2026-2032年

Prostate Cancer Diagnostics Market by Product Type, Test Type, Technology, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，攝護腺癌診斷市場價值將達到 16.3 億美元，到 2026 年將成長到 18.3 億美元，到 2032 年將達到 43.3 億美元，複合年成長率為 14.97%。

主要市場統計數據
基準年 2025 16.3億美元
預計年份：2026年 18.3億美元
預測年份 2032 43.3億美元
複合年成長率 (%) 14.97%

前列腺癌的診斷正處於快速發展的生物醫學與不斷演變的臨床實踐模式之間的關鍵交匯點。近年來，診斷流程已從過度依賴單一篩檢工具發展為結合生物標記、分子平台、影像引導切片檢查和先進成像系統的綜合策略。因此，臨床、商業和監管領域的相關人員正在重新評估如何更早發現疾病、更準確地進行風險分層、減少不必要的侵入性操作，同時維持或改善治療效果。

在此背景下，診斷技術的創新正受到多種技術趨勢的驅動。生物標記和檢測套組的開發已超越了基礎蛋白質檢測，涵蓋了基因和分子檢測套組，並通常結合先進的分析技術。 CT、MRI、PET和超音波等影像系統正不斷最佳化，以適應前列腺檢查的需求，而切片檢查技術和方法的改進也持續影響組織取樣策略。這些進步共同重塑了臨床路徑，並促成了更個人化的診斷和治療方案。

隨著我們逐漸擺脫傳統模式，檢查室、醫院、門診手術中心和研究機構都在調整工作流程和資本投資計劃，以適應診斷技術的進步。臨床團隊在採用新的檢測方法和模式的同時，保險公司和政策制定者也在重新評估福利框架和臨床指南。本執行摘要的其餘部分將概述變革性變化、結構性阻力（例如費用變化的影響）、市場區隔洞察、區域趨勢、競爭對手動態，並為引領產業變革的領導者提供切實可行的建議。

新的多模態診斷策略、分散式檢查和不斷變化的報銷預期如何從根本上改變前列腺癌的治療方式。

攝護腺癌的診斷格局正在經歷一場變革，這既得益於科學突破，也得益於臨床實務的需求。分子診斷技術，包括次世代定序和基於PCR的檢測，已從小眾的研究工具發展成為臨床上用於風險分層和指導切片檢查決策的有效手段。同時，先進的影像技術也日益融入介入治療流程，從而實現標靶切片檢查並降低診斷的不確定性。

了解累積關稅變更對醫療診斷設備採購和部署的營運、採購和供應鏈的連鎖影響。

政策變化和貿易措施將對醫療設備診斷設備的供應鏈造成顯著的營運壓力，而2025年的累積關稅調整將產生一系列累積效應，需要認真考慮。影響醫療設備器械、試劑和耗材的關稅上調往往會提高影像系統、切片檢查設備和試劑盒的到貨成本，從而影響醫院、診斷中心和門診手術中心的採購週期。在資本預算受限的情況下，決策者可能會優先考慮已證實具有臨床效用和成本效益的產品，即使新設備具有明顯的臨床益處，也可能會推遲其引進。

綜合細分分析將產品、測試類型、最終用戶、技術和應用維度連結起來，以揭示策略重點和臨床工作流程機會。

對細分市場的詳細分析揭示了臨床需求、技術能力和最終用戶情況的交匯點，從而創造了差異化的機會。產品類型細分包括生物標記試劑盒、切片穿刺針和成像系統。生物標記試劑盒進一步細分為基因檢測套組、分子診斷試劑盒和PSA檢測，而影像系統則涵蓋CT系統、MRI系統、PET系統和超音波系統。這種層級式產品分類與檢測類型細分相交。檢測類型包括切片檢查、影像檢查、分子檢測和PSA檢測。影像檢查為CT掃描、MRI掃描、PET掃描和超音波檢測，而分子檢測則分為NGS檢測和PCR檢測。從產品和檢測類型兩個觀點來看，臨床工作流程中最易受干擾的領域以及診斷和介入治療程序整合能夠帶來最大臨床療效的領域都變得清晰可見。

決定美洲、歐洲、中東和非洲以及亞太地區前列腺癌診斷技術普及程度的區域趨勢和基礎設施差異。

區域趨勢持續影響著前列腺癌診斷的普及曲線和商業化策略。在美洲，醫療系統和私立機構正透過投資分子診斷平台和先進影像系統來滿足臨床對更精準診斷的需求，同時強調基於價值的採購和以結果為導向的證據產生。相較之下，歐洲、中東和非洲（EMEA）地區的情況較為複雜，由於監管協調、國家篩檢政策以及醫療基礎設施的差異，各地的普及率各不相同。一些西歐市場較早採用了整合診斷路徑，而其他市場則專注於改善基礎影像和檢測服務的可近性。

平台創新、策略聯盟和證據產生所驅動的競爭動態，正在加速整合診斷解決方案和服務導向方法的商業化。

前列腺癌診斷生態系統的競爭活動以平台升級、策略夥伴關係以及與學術和臨床中心持續進行實證合作為特徵。成熟的醫療設備和診斷設備製造商不斷改進CT、MRI、PET和超音波等影像系統，以更好地支援前列腺癌特異性方案和融合影像引導切片檢查工作流程。同時，分子診斷專家正在擴展其檢測項目，並簡化次世代定序和基於PCR的檢測工作流程，以促進臨床應用和快速出具結果。

為技術開發商、醫療保健系統和投資者提供切實可行的策略行動，以加速技術應用、保障供應鏈並展現永續的臨床價值。

產業領導者可以採取多項切實可行的措施，以確保臨床意義和商業性韌性。首先，透過投資能夠顯著降低診斷不確定性和後續流程負擔的檢測方法和檢測手段，使產品開發與臨床路徑保持一致。其次，優先與臨床中心和診斷網路建立合作關係，以簡化部署流程並共同設計工作流程，從而在切片檢查和治療決策中顯著改善患者選擇。透過這些措施，供應商可以縮短引進週期並獲得臨床醫生的認可。

為了確保獲得嚴謹的見解，我們採用了一種綜合性的、多方法的研究途徑，結合了臨床訪談、文獻整合、方案案例研究和供應鏈情境分析。

本報告整合了多種調查方法提供的證據，以確保研究結果的可靠性和可重複性。主要研究活動包括對醫院、門診手術中心、診斷中心和實驗室的臨床專家、實驗室經理和採購經理進行結構化訪談，以了解他們對工作流程整合、採購標準和臨床效用的實際觀點。次要分析包括對同行評審文獻、臨床指南、監管申報文件、成像和檢測平台的技術規範以及製造商文件進行嚴格審查，以深入了解技術能力和檢驗流程。

整合臨床、營運和政策因素，以確定診斷技術的創新是否能改善患者預後並帶來永續的醫療保健價值。

前列腺癌的診斷正朝著更整合、個人化和實證的診療模式轉變。分子檢測、先進的生物標記檢測和影像系統的整合，使臨床醫生能夠更明智地決定何時進行切片檢查、何時進行標靶取樣以及何時病患監測。同時，關稅和醫保報銷預期變化等供應鏈調整帶來的營運壓力，凸顯了製造商和醫療保健系統戰略靈活性的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：前列腺癌診斷市場：依產品類型分類

  • 生物標記和試劑盒
    • 基因檢測套組
    • 分子診斷試劑盒
    • PSA檢測
  • 切片穿刺針
  • 醫學影像系統
    • CT系統
    • 磁振造影系統
    • PET系統
    • 超音波診斷設備

第9章 攝護腺癌診斷市場：檢測類型

  • 切片檢查
  • 影像檢查
    • CT掃描
    • 核磁共振掃描
    • PET掃描
    • 超音波檢查
  • 分子檢測
    • NGS檢測
    • PCR檢測
  • PSA檢測

第10章 攝護腺癌診斷市場：依技術分類

  • 診斷影像
    • CT影像方式
    • 磁振造影技術
    • PET影像方式
    • 超音波檢查
  • 免疫檢測
    • ELISA
    • RIA
  • 分子診斷
    • NGS技術
    • PCR技術

第11章 攝護腺癌診斷市場：依最終用戶分類

  • 門診手術中心
  • 診斷中心
  • 醫院和診所
  • 研究所

第12章 攝護腺癌診斷市場：依應用分類

  • 基因檢測
  • 初步診斷
  • 後續觀察跟進和監測

第13章 攝護腺癌診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 攝護腺癌診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 攝護腺癌診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國前列腺癌診斷市場

第17章：中國前列腺癌診斷市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • bioMerieux SA
  • Danaher Corporation
  • Hologic, Inc.
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • MDxHealth SA
  • Myriad Genetics, Inc.
  • Proteomedix AG
  • QIAGEN NV
  • Quest Diagnostics, Inc.
  • Roche Diagnostics International AG
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Veracyte, Inc.
Product Code: MRR-A339DAEFAC09

The Prostate Cancer Diagnostics Market was valued at USD 1.63 billion in 2025 and is projected to grow to USD 1.83 billion in 2026, with a CAGR of 14.97%, reaching USD 4.33 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.63 billion
Estimated Year [2026] USD 1.83 billion
Forecast Year [2032] USD 4.33 billion
CAGR (%) 14.97%

Prostate cancer diagnostics sits at a pivotal intersection between rapidly advancing biomedical science and shifting clinical practice patterns. Recent years have seen diagnostic pathways evolve from a heavy reliance on single-measure screening tools to integrated strategies that combine biomarkers, molecular platforms, image-guided biopsy, and advanced imaging systems. As a result, stakeholders across clinical, commercial, and regulatory domains are reevaluating how to identify disease earlier, stratify risk more precisely, and reduce unnecessary invasive procedures while preserving or improving outcomes.

In this context, diagnostics innovation is driven by multiple technological streams. Biomarker and kit development has matured beyond basic protein assays to include genetic and molecular testing kits, which are frequently paired with sophisticated analytics. Imaging systems such as CT, MRI, PET, and ultrasound are increasingly optimized for prostate applications, and biopsy technology and technique refinement continue to shape tissue acquisition strategy. Together, these developments are reshaping clinical pathways and enabling more personalized approaches to diagnosis and management.

Transitioning from traditional paradigms, laboratories, hospitals, ambulatory surgical centers, and research laboratories are adapting workflows and capital plans to accommodate these diagnostic advances. As clinical teams integrate new tests and modalities, payers and policymakers are simultaneously reassessing coverage frameworks and care guidelines. The remainder of this executive summary synthesizes transformative shifts, structural headwinds such as tariff implications, segmentation intelligence, regional dynamics, competitor actions, and actionable recommendations for leaders navigating this evolving landscape.

How emerging multimodal diagnostic strategies, decentralized testing, and evolving reimbursement expectations are fundamentally altering prostate cancer care delivery

The diagnostic landscape for prostate cancer is experiencing transformative shifts driven by both scientific breakthroughs and operational imperatives. Molecular diagnostics, including next-generation sequencing and PCR-based assays, have transitioned from niche research tools to clinically relevant instruments that inform risk stratification and guide biopsy decisions. At the same time, advanced imaging modalities have become more tightly integrated with interventional workflows, enabling targeted biopsies and reducing diagnostic uncertainty.

Another major shift is the movement toward multimodal diagnostic algorithms that combine biomarkers, imaging, and clinical parameters to refine patient selection for biopsy and therapy. This integrative approach reduces overdiagnosis and supports more precise treatment pathways. Furthermore, decentralization of diagnostics is advancing as ambulatory surgical centers and diagnostic centers adopt point-of-care and near-patient testing options, altering referral flows and capital investment decisions made by hospitals.

Regulatory and reimbursement landscapes are also evolving to accommodate new diagnostic paradigms. Payers are increasingly focused on value-based metrics and real-world evidence, which elevates the importance of demonstrating clinical utility beyond analytical performance. Consequently, companies and clinical teams must align evidence generation with outcome-focused endpoints. Taken together, these shifts are accelerating a move from one-size-fits-all screening toward personalized diagnostic strategies that better match patient risk profiles and care goals.

Understanding the cascading operational, procurement, and supply chain consequences of cumulative tariff changes on medical diagnostics procurement and deployment

Policy changes and trade actions can exert meaningful operational pressure on medical device and diagnostic supply chains, and the aggregation of tariff adjustments in 2025 has created a set of cumulative impacts that warrant close attention. Tariff increases affecting medical equipment, reagents, and consumables tend to raise landed costs for imaging systems, biopsy devices, and kits, which in turn influences procurement cycles for hospitals, diagnostic centers, and ambulatory surgical centers. When capital budgets are constrained, decision-makers prioritize proven clinical utility and cost-effectiveness, which can slow adoption of newer devices even when they offer clear clinical benefits.

Beyond immediate cost implications, tariffs can accelerate regional sourcing strategies and supplier diversification efforts. Manufacturers and purchasers may respond by reshoring certain production activities, qualifying additional suppliers in different geographies, or seeking tariff classification optimizations to mitigate duty exposure. These responses often require lead time and investment, and they can create temporary bottlenecks in availability of specialized consumables or complex imaging components. In parallel, suppliers may adjust pricing models, renegotiate distribution agreements, or introduce bundled service offerings to preserve market access.

Importantly, clinical operations feel secondary effects as procurement uncertainty influences scheduling for capital upgrades and training programs. As a result, health systems may defer nonurgent technology refreshes, extend the lifecycle of existing assets, or adopt selective deployment strategies that concentrate new capabilities in centers of excellence. For stakeholders in the diagnostic ecosystem, proactive supply chain and policy monitoring, coupled with contingency planning, are essential to navigate the persistent ripple effects of tariff shifts.

Integrated segmentation analysis that links product, test type, end-user, technology, and application dimensions to reveal strategic priorities and clinical workflow opportunities

A nuanced view of segmentation reveals where clinical need, technology capability, and end-user context converge to create differentiated opportunities. Product type segmentation spans Biomarkers & Kits, Biopsy Needles, and Imaging Systems, with Biomarkers & Kits further differentiated into Genetic Testing Kits, Molecular Diagnostic Kits, and PSA Tests, and Imaging Systems encompassing CT Systems, MRI Systems, PET Systems, and Ultrasound Systems. This layered product taxonomy intersects with test-type segmentation, which includes Biopsy, Imaging Tests, Molecular Tests, and PSA Test, while Imaging Tests are broken into CT Tests, MRI Tests, PET Tests, and Ultrasound Tests and Molecular Tests are delineated between NGS Tests and PCR Tests. Together, product and test-type perspectives illuminate where clinical workflows are most disrupted and where integration between diagnostics and interventional procedures yields the greatest clinical return.

Examining end-user segmentation clarifies adoption pathways: Ambulatory Surgical Centers, Diagnostic Centers, Hospitals & Clinics, and Research Laboratories each have distinct capital profiles, throughput expectations, and clinical scope, which shape technology selection and service models. Technology-focused segmentation further refines opportunity areas by distinguishing Imaging Modalities, Immunoassays, and Molecular Diagnostics, with Imaging Modalities comprising CT, MRI, PET, and Ultrasound Modalities, Immunoassays including ELISA and RIA platforms, and Molecular Diagnostics covering NGS and PCR technologies. Finally, application segmentation-Genetic Testing, Initial Diagnosis, and Monitoring & Follow-Up-maps to different clinical decision points and evidence requirements, with monitoring applications often demanding longitudinal data integration and standardized reporting.

By synthesizing these segmentation lenses, stakeholders can better target product development and commercialization strategies that account for modality-specific workflow integration, end-user procurement behavior, and the differing evidence standards across initial diagnosis versus longitudinal monitoring contexts.

Regional dynamics and infrastructure variations that determine adoption trajectories for prostate cancer diagnostics across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to shape adoption curves and commercialization strategies in prostate cancer diagnostics. In the Americas, health systems and private providers are responding to clinical demand for precision diagnostics by investing in molecular platforms and advanced imaging systems, while also emphasizing value-based procurement and outcome-driven evidence generation. In contrast, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization, national screening policies, and variable healthcare infrastructure produce diverse adoption rhythms; certain Western European markets are early adopters of integrated diagnostic pathways, whereas other markets are focused on improving access to basic imaging and laboratory services.

Asia-Pacific reflects a mix of rapid technology adoption in urban tertiary centers and continued capacity-building in regional hospitals and diagnostic centers. Demand in that region is driven by both public health initiatives and private-sector investments in diagnostic innovation. Across all regions, ambulatory surgical centers and diagnostic centers are important vectors for dissemination of new testing modalities and for decentralizing care. Moreover, the interplay between local regulatory frameworks, reimbursement environments, and supplier footprint determines how quickly new biomarker assays, imaging systems, and molecular tests transition from clinical research to routine practice.

Consequently, companies and healthcare organizations must adopt regionally tailored strategies that account for infrastructure maturity, payer expectations, and clinical guideline adoption. Local clinical champions, targeted evidence generation, and adaptive deployment models are essential to bridge global innovation with regional implementation realities.

Competitive dynamics driven by platform innovation, strategic partnerships, and evidence generation that accelerate integrated diagnostic solutions and service-oriented commercialization

Competitive activity within the prostate cancer diagnostics ecosystem is characterized by sustained investment in platform enhancements, strategic partnerships, and evidence-building collaborations with academic and clinical centers. Established medical device and diagnostic manufacturers continue to refine imaging systems across CT, MRI, PET, and ultrasound modalities to better support prostate-specific protocols and fusion-guided biopsy workflows. At the same time, specialist firms in molecular diagnostics are expanding assay menus and streamlining workflows for next-generation sequencing and PCR-based tests to facilitate clinical integration and faster turnaround times.

Partnerships between kit manufacturers and imaging or interventional device companies are becoming more common as the market moves toward bundled diagnostic solutions that span biomarker testing, image-guided sampling, and downstream molecular analysis. Additionally, service models that pair capital equipment with training, workflow optimization, and post-sale data services are gaining traction among end-users seeking to reduce the complexity of deploying new technologies. Research laboratories and academic centers remain key collaborators for novel biomarker validation and clinical utility studies, enabling commercial players to build stronger real-world evidence packages.

Given these dynamics, successful companies prioritize cross-functional collaboration, regulatory strategy alignment, and robust post-market surveillance to demonstrate clinical value. They also invest in scalable manufacturing and diversified supply chains to mitigate policy and tariff-related disruptions while preserving market responsiveness.

Practical strategic actions for technology developers, health systems, and investors to accelerate adoption, secure supply chains, and demonstrate enduring clinical value

Industry leaders can take several actionable steps to secure clinical relevance and commercial resilience. First, align product development with clinical pathways by investing in modalities and assays that demonstrably reduce diagnostic uncertainty and downstream procedural burden. Second, prioritize partnerships with clinical centers and diagnostic networks to co-design workflows that simplify implementation and deliver measurable improvements in patient selection for biopsy and treatment decisions. By doing so, vendors can shorten adoption cycles and foster clinician buy-in.

Third, strengthen supply chain resilience through diversification of manufacturing, qualification of secondary suppliers for critical consumables, and proactive tariff and trade policy monitoring. Fourth, adopt flexible commercial models that combine capital equipment with outcome-linked services, training, and data analytics to lower adoption hurdles for end-users with constrained budgets. Fifth, invest in real-world evidence generation that aligns with payer value frameworks; pragmatic studies and registry-based evidence are particularly valuable in demonstrating clinical utility across diverse care settings.

Finally, tailor regional go-to-market strategies to local regulatory and reimbursement realities while leveraging centers of excellence to demonstrate clinical and operational value. When leaders execute these priorities, they improve the probability that new diagnostic technologies will transition smoothly from innovation to routine clinical practice.

Comprehensive multi-method research approach combining primary clinical interviews, literature synthesis, protocol case studies, and supply chain scenario analysis to ensure rigorous insights

This report synthesizes evidence from multiple methodological pillars to ensure robust, reproducible insights. Primary research activities involved structured interviews with clinical specialists, laboratory directors, and procurement leaders across hospitals, ambulatory surgical centers, diagnostic centers, and research laboratories to capture frontline perspectives on workflow integration, purchasing criteria, and clinical utility. Secondary analysis encompassed a rigorous review of peer-reviewed literature, clinical guidelines, regulatory filings, technical specifications for imaging and assay platforms, and manufacturer documentation to contextualize technological capabilities and validation pathways.

In addition, case studies and protocol reviews were used to assess how molecular diagnostics, imaging systems, biomarkers, and biopsy techniques are being operationalized in real-world settings. Supply chain and policy impacts were evaluated through scenario analysis and expert consultation to identify plausible operational responses to tariff shifts and component availability constraints. Quality assurance procedures included cross-validation of interview findings with published clinical outcomes and triangulation across multiple data sources to limit bias and ensure consistency.

The methodological approach emphasizes transparency and replicability, with documented interview protocols, source annotations, and a clear statement of inclusion criteria for secondary literature. This multi-method strategy affords a balanced view of both technological potential and the pragmatic barriers that influence adoption across varied healthcare environments.

Synthesis of clinical, operational, and policy factors that will determine whether diagnostic innovations translate into improved patient outcomes and sustainable healthcare value

Prostate cancer diagnostics is transitioning toward a more integrated, personalized, and evidence-driven model of care. The convergence of molecular testing, refined biomarker assays, and enhanced imaging systems is enabling clinicians to make more informed decisions about when to biopsy, how to target sampling, and how to monitor patients over time. Meanwhile, operational pressures such as tariff-induced supply chain adjustments and changing reimbursement expectations underscore the need for strategic agility among manufacturers and health systems.

Looking ahead, the most influential success factors will be demonstrable clinical utility, workflow-friendly solutions, and resilient commercialization strategies that respond to local infrastructure and policy realities. Collaboration between technology providers, clinical sites, and payers will be central to aligning evidence generation with the decision-making criteria that govern adoption. By focusing on integrated diagnostic pathways and pragmatic evidence, stakeholders can reduce unnecessary procedures, optimize resource use, and ultimately improve patient-centered outcomes.

In sum, the diagnostic ecosystem is positioned to deliver meaningful improvements in prostate cancer care, provided that innovation is paired with a clear articulation of clinical benefit and an operational plan that mitigates supply and policy-related risks.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Prostate Cancer Diagnostics Market, by Product Type

  • 8.1. Biomarkers & Kits
    • 8.1.1. Genetic Testing Kits
    • 8.1.2. Molecular Diagnostic Kits
    • 8.1.3. Psa Tests
  • 8.2. Biopsy Needles
  • 8.3. Imaging Systems
    • 8.3.1. Ct Systems
    • 8.3.2. Mri Systems
    • 8.3.3. Pet Systems
    • 8.3.4. Ultrasound Systems

9. Prostate Cancer Diagnostics Market, by Test Type

  • 9.1. Biopsy
  • 9.2. Imaging Tests
    • 9.2.1. Ct Tests
    • 9.2.2. Mri Tests
    • 9.2.3. Pet Tests
    • 9.2.4. Ultrasound Tests
  • 9.3. Molecular Tests
    • 9.3.1. Ngs Tests
    • 9.3.2. Pcr Tests
  • 9.4. Psa Test

10. Prostate Cancer Diagnostics Market, by Technology

  • 10.1. Imaging Modalities
    • 10.1.1. Ct Modalities
    • 10.1.2. Mri Modalities
    • 10.1.3. Pet Modalities
    • 10.1.4. Ultrasound Modalities
  • 10.2. Immunoassays
    • 10.2.1. Elisa
    • 10.2.2. Ria
  • 10.3. Molecular Diagnostics
    • 10.3.1. Ngs Technologies
    • 10.3.2. Pcr Technologies

11. Prostate Cancer Diagnostics Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Diagnostic Centers
  • 11.3. Hospitals & Clinics
  • 11.4. Research Laboratories

12. Prostate Cancer Diagnostics Market, by Application

  • 12.1. Genetic Testing
  • 12.2. Initial Diagnosis
  • 12.3. Monitoring & Follow-Up

13. Prostate Cancer Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Prostate Cancer Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Prostate Cancer Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Prostate Cancer Diagnostics Market

17. China Prostate Cancer Diagnostics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. bioMerieux SA
  • 18.7. Danaher Corporation
  • 18.8. Hologic, Inc.
  • 18.9. Illumina, Inc.
  • 18.10. Laboratory Corporation of America Holdings
  • 18.11. MDxHealth SA
  • 18.12. Myriad Genetics, Inc.
  • 18.13. Proteomedix AG
  • 18.14. QIAGEN N.V.
  • 18.15. Quest Diagnostics, Inc.
  • 18.16. Roche Diagnostics International AG
  • 18.17. Siemens Healthineers AG
  • 18.18. Thermo Fisher Scientific Inc.
  • 18.19. Veracyte, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 250. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 251. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 253. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 254. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 256. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 257. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 258. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 286. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 289. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 290. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 292. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 293. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 295. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 296. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 297. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 299. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 300. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 302. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 303. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 305. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 306. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION